Department of Anesthesiology, Tanta University Hospital, Faculty of Medicine, Tanta, 31527, Egypt.
J Clin Anesth. 2011 Nov;23(7):544-8. doi: 10.1016/j.jclinane.2011.02.007.
To determine whether orally administered atenolol provides an optimal surgical field in comparison to intravenous sodium nitroprusside or esmolol during tympanoplasty.
Randomized, double-blinded study.
Operating room in a university hospital.
105 ASA physical status 1 and 2 adult patients undergoing tympanoplasty.
Patients were randomized to three groups to receive either oral atenolol 50 mg twice daily for one day prior to surgery (Group I), intraoperative nitroprusside infusion (Group II), or intraoperative esmolol infusion (Group III).
Quality of the operative field, mean arterial pressure, and heart rate were assessed. Blood gases, liver enzymes, cardiac troponin I, creatine kinase isoenzyme-MB release, blood urea nitrogen, and creatinine concentrations also were measured.
Time to achieve target surgical field was significantly reduced in the atenolol group versus the other groups (8.3 ± 3.2, 28.2 ± 6.4, and 17.2 ± 5.3 min, respectively). Heart rate significantly decreased in the atenolol and esmolol groups versus the nitroprusside group (P < 0.0001). Mean arterial pressure after extubation and frequency of rebound hypertension were comparable in the groups. No significant changes in cardiac enzymes, renal and hepatic function, or acid-base status were noted.
Although the three drugs are acceptable for obtaining an optimum surgical field, preoperative oral beta blocker appeared to be rapid in onset and was simpler to implement.
比较在鼓室成形术中静脉注射硝普钠或艾司洛尔与口服阿替洛尔,哪种方法能提供更优的手术视野。
随机、双盲研究。
大学医院手术室。
105 例 ASA 身体状况 1 级和 2 级行鼓室成形术的成年患者。
患者随机分为三组,分别接受术前一天口服阿替洛尔 50mg,每日两次(I 组)、术中硝普钠输注(II 组)或术中艾司洛尔输注(III 组)。
评估手术视野质量、平均动脉压和心率。还测量血气、肝酶、心肌肌钙蛋白 I、肌酸激酶同工酶-MB 释放、血尿素氮和肌酐浓度。
与其他两组相比,阿替洛尔组达到目标手术视野的时间明显缩短(分别为 8.3 ± 3.2、28.2 ± 6.4 和 17.2 ± 5.3 分钟)。与硝普钠组相比,阿替洛尔组和艾司洛尔组的心率明显下降(P < 0.0001)。拔管后平均动脉压和反弹性高血压的发生率在各组之间相似。未观察到心脏酶、肾功能和肝功能或酸碱状态的显著变化。
尽管这三种药物都可用于获得最佳手术视野,但术前口服β受体阻滞剂起效更快,实施更简单。